Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.50 |
| ▸ | PRKCI | P41743 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL252955 | 0.85 | HCRTR1 (0.43) | ATRPRKCIKDM4EHCRTR1HCRTR2 | |
| SCHEMBL6429865 | 0.82 | NPC1 (0.55) | PRKCIMEN1ALDH1A1GAAMAPT | |
| SCHEMBL251660 | 0.80 | NPC1 (0.51) | RAB9A | |
| SCHEMBL16826513 | 0.79 | HCRTR1 (0.42) | ALDH1A1GAAMAPTKDM4EHCRTR1 | |
| SCHEMBL18039131 | 0.79 | HCRTR1 (0.44) | ALDH1A1MAPTKDM4EHCRTR1HCRTR2 | |
| SCHEMBL1900468 | 0.76 | GRM4 (0.53) | ATRPRKCIMEN1ALDH1A1GAA | |
| SCHEMBL13201028 | 0.73 | ATR (0.61) | ATRPRKCIMEN1ALDH1A1GAA | |
| SCHEMBL938982 | 0.72 | GRM4 (0.69) | ATRPRKCIMEN1ALDH1A1GAA | |
| SCHEMBL5936350 | 0.72 | HTT (0.60) | ATRPRKCIMEN1ALDH1A1GAA | |
| SCHEMBL7974510 | 0.72 | ATR (0.59) | ATRPRKCIMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2017-07-13 | — | — | US | disclosed |
| US-9586932-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2016-05-12 | — | — | US | disclosed |
| US-9067933-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140018370-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8598360-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8552196-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8378108-B2 | Apoptosis signal-regulating kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018370-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | ATR 283/4885PRKCI 366/4885MEN1 3251/4885 |
| US-20170196844-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | ATR 283/4885PRKCI 366/4885MEN1 3251/4885 |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | ATR 302/4885PRKCI 329/4885MEN1 3305/4885 |
| US-20160130251-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | ATR 283/4885PRKCI 366/4885MEN1 3251/4885 |
| US-20130035339-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, MAP3K6 | ATR 261/4885PRKCI 361/4885MEN1 3166/4885 |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | ATR 283/4885PRKCI 366/4885MEN1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.